- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04671628
Effects of a 2-week Relaxing Music Intervention on Anxiety, Stress, and Gut Symptoms in Aerobic Exercisers
October 31, 2023 updated by: Patrick Wilson, PhD, Old Dominion University
The objective of the study is to determine the impacts of a 2-week relaxing music intervention on stress, anxiety, and gut symptoms in individuals who regularly perform structured aerobic exercise.
Gut symptoms like bloating, reflux, cramping, nausea, etc. are relatively common during prolonged aerobic exercise.
In addition, previous research has established that levels of anxiety and stress are associated with a higher occurrence of these gut symptoms.
Relaxing music has reduced anxiety in certain populations, but currently, no studies are available on its effects on anxiety, stress, and gut symptoms in people who regularly do aerobic exercise.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
19
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Patrick Wilson
- Phone Number: 7576834783
- Email: pbwilson@odu.edu
Study Locations
-
-
Virginia
-
Norfolk, Virginia, United States, 23529
- Human Performance Laboratory
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- be at least 18 years of age
- do 120+ minutes per week of planned/structured aerobic exercise of at least moderate intensity
- have had at least mild anxiety over the past 2 weeks (GAD-7 score of 5 or more)
- not currently on a psychotropic medication, or if they are on one, they must have been on a stable dose for the past three months
- not currently listening to music for relaxation purposes regularly (>60 minutes per week)
- have at least sometimes experienced gut symptoms (nausea, gas, bloating, cramping, side stitching, urge to defecate, etc.) during aerobic exercise sessions over the last month
- have access to the internet
Exclusion Criteria:
- not at least 18 years of age
- don't do 120+ minutes per week of planned/structured aerobic exercise of at least moderate intensity
- haven't had at least mild anxiety over the past 2 weeks (GAD-7 score of 5 or more)
- have recently started taking a psychotropic medication (within past 3 months)
- currently listening to music for relaxation purposes regularly (>60 minutes per week)
- have never or rarely experienced gut symptoms (nausea, gas, bloating, cramping, side stitching, urge to defecate, etc.) during aerobic exercise sessions over the last month
- don't have internet access
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control
|
|
Experimental: Relaxing music
|
Participants will be asked to listen to relaxing music for 30 minutes each day.
They will allowed to choose between several playlists based on their preference.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in gastrointestinal symptom severity
Time Frame: The intervention will last 2 weeks. Gastrointestinal symptoms will be collected for a 1-week period before the intervention and during the 2nd week of the intervention
|
The severity of several gastrointestinal symptoms will be assessed on a validated 0-10 scale.
|
The intervention will last 2 weeks. Gastrointestinal symptoms will be collected for a 1-week period before the intervention and during the 2nd week of the intervention
|
Change in anxiety levels
Time Frame: The intervention will last 2 weeks. The General Anxiety Disorder-7 will be assessed before the intervention begins and again after 2 weeks.
|
Levels of anxiety will be assessed with the General Anxiety Disorder-7 questionnaire.
Scores on the General Anxiety Disorder-7 range from 0 to 21, with higher scores indicating higher levels of anxiety.
|
The intervention will last 2 weeks. The General Anxiety Disorder-7 will be assessed before the intervention begins and again after 2 weeks.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in visceral sensitivity
Time Frame: The intervention will last 2 weeks. The Visceral Sensitivity Index will be assessed before the intervention begins and again after 2 weeks.
|
Perceptions of visceral sensitivity will be assessed via the Visceral Sensitivity Index.
Scores on the Visceral Sensitivity Index can range from 0 to 75, with higher scores indicating a higher level of visceral sensitivity.
|
The intervention will last 2 weeks. The Visceral Sensitivity Index will be assessed before the intervention begins and again after 2 weeks.
|
Change in perceived stress
Time Frame: The intervention will last 2 weeks. The Perceived Stress Scale 14 will be assessed before the intervention begins and again after 2 weeks.
|
Perceived life stress will be evaluated with the Perceived Stress Scale 14. Scores on this scale can range from 0 to 56, will higher scores indicating greater amounts of stress.
|
The intervention will last 2 weeks. The Perceived Stress Scale 14 will be assessed before the intervention begins and again after 2 weeks.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2021
Primary Completion (Actual)
October 1, 2023
Study Completion (Actual)
October 1, 2023
Study Registration Dates
First Submitted
December 8, 2020
First Submitted That Met QC Criteria
December 15, 2020
First Posted (Actual)
December 17, 2020
Study Record Updates
Last Update Posted (Actual)
November 1, 2023
Last Update Submitted That Met QC Criteria
October 31, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1690558
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anxiety
-
AstraZenecaCompletedAnxiety Disorders | Anxiety | Anxiety Neuroses | Anxiety StatesUnited States
-
Prisma Health-UpstateCompletedAnxiety | Anxiety, Separation | Separation Anxiety | Anxiety Generalized
-
Ann & Robert H Lurie Children's Hospital of ChicagoUniversity of California, Los Angeles; University of CincinnatiRecruitingAnxiety, Separation | Anxiety, Social | Anxiety, GeneralizedUnited States
-
Yale UniversityNational Institute of Mental Health (NIMH)Active, not recruitingGeneralized Anxiety Disorder | Anxiety Disorder of Childhood | Separation Anxiety Disorder of Childhood | Social Anxiety Disorder of ChildhoodUnited States
-
Nazife Begüm KARANCompletedDental Anxiety | Sedative; Anxiety DisorderTurkey
-
Loyola UniversityCompletedAnxiety | Anxiety State | Procedural AnxietyUnited States
-
Dr. Nazanin AlaviActive, not recruitingGeneralized Anxiety Disorder | AnxietyCanada
-
ProofPilotFisher WallaceActive, not recruitingGeneralized Anxiety Disorder | Anxiety | Generalized AnxietyUnited States
-
Loma Linda UniversityCompletedParental/Caregiver Anxiety | Child's AnxietyUnited States
-
UCLH/UCL Joint Research OfficeMedical Research Council; Camden and Islington NHS Trust; Central and North West...RecruitingAnxiety Disorders | Anxiety | Anxiety Depression | CBT | Anxiety Disorders and Symptoms | Anxiety Generalized | Generalised Anxiety Disorder | Anxiety Disorder; Mixed With Depression (Mild) | Anxiety Disorder GeneralizedUnited Kingdom
Clinical Trials on Relaxing music
-
Centre Hospitalier Universitaire de NiceRecruiting
-
Old Dominion UniversityCompletedMetabolismUnited States
-
Min-Sheng General HospitalCompletedLiver Diseases | Heart Failure | Stroke | Pneumonia | Septic Shock | Respiratory Failure | Trauma | Acute Kidney Injury | Diabetic Ketoacidosis | Head Injury | GastroIntestinal Bleeding | Intracerebral Hemorrhage | Heart Disease, IschemicTaiwan
-
Rambam Health Care CampusUnknownParkinson's Disease
-
Milton S. Hershey Medical CenterRecruiting
-
The Nethersole School of NursingCompleted
-
Chonbuk National University HospitalCompletedSchizophrenia | Schizoaffective Disorder | Psychotic Disorder Not Otherwise Specified | Schizophreniform Disorders | Schizophrenia Spectrum DisordersKorea, Republic of
-
Maria Sklodowska-Curie National Research Institute...RecruitingPain, Postoperative | Colonic Neoplasms | HypnotherapyPoland
-
University of ViennaCompletedStress, Psychological | Stress, Physiological | Discrimination, RacialAustria
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedBreast Cancer | Chemotherapy-induced Nausea and Vomiting | Prostate Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Gastrointestinal Cancer | Disease (or Disorder); GynecologicalUnited States